EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...

A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that ...

A new study of Dexcom's G4 Platinum continuous glucose monitor showed that more than half of the participants experienced a 10% or higher reduction in an important indicator for developing ...

In the not-so-distant future, the hottest new tech on the playground could be an artificial pancreas system. A closed-loop system that combines Dexcom’s continuous glucose monitor with Tandem Diabetes ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: The COMPASS Program, ...

For UK-based patients with Type 1 diabetes, the Dexcom G6 rtCGM device is associated with significant improvements in clinical outcomes [1],[2] and is highly-cost effective over patient lifetimes ...

To avoid bias, the study did use aggressive titration protocols that might be found in a real-world setting. Still, patients using CGM saw greater reductions in A1C and more time in range. Continuous ...

A new clinical trial to investigate the use of artificial pancreas system is set to begin, bringing in touchscreen insulin pump maker Tandem Diabetes Care; Dexcom, which makes continuous glucose ...

To honour the strength of the diabetes community, Dexcom to host uplifting Puppy Yoga Event in London with Roxy Horner and Henry Slade New research from Dexcom shows that 84% of people agree that ...

For UK-based patients with Type 1 diabetes, the Dexcom G6 rtCGM device is associated with significant improvements in clinical outcomes [1],[2] and is highly-cost effective over patient lifetimes ...